Ranitidine

Bombesin is a gastrin-releasing peptide analog that binds bombesin and GRP receptors. Derivatives of bombesin are currently under investigation as cancer imaging tools, as bombesin receptors are often overexpressed in tumor tissues.

Bombesin is a gastrin-releasing peptide analog that binds bombesin and GRP receptors. Derivatives of bombesin are currently under investigation as cancer imaging tools, as bombesin receptors are often overexpressed in tumor tissues.

Bombesin is a gastrin-releasing peptide analog that binds bombesin and GRP receptors. Derivatives of bombesin are currently under investigation as cancer imaging tools, as bombesin receptors are often overexpressed in tumor tissues.

Biochem/physiol Actions Ranirestat (AS-3201) is an aldose reductase (AR) inhibitor. Aldose reductase is a rate-limiting enzyme in the conversion of D-glucose to fructose via D-sorbitol.

Ranirestat (AS-3201) potent and orally active aldose reductase (AR) inhibitor with IC 50 s of 11 nM and 15 nM for rat lens AR and recombinant human AR , respectively, and a K i of 0.38 nM for recombinant human AR . Ranirestat has the potential for

Ranirestat (AS-3201) potent and orally active aldose reductase (AR) inhibitor with IC 50 s of 11 nM and 15 nM for rat lens AR and recombinant human AR , respectively, and a K i of 0.38 nM for recombinant human AR . Ranirestat has the potential for

Ranirestat (AS-3201) potent and orally active aldose reductase (AR) inhibitor with IC 50 s of 11 nM and 15 nM for rat lens AR and recombinant human AR , respectively, and a K i of 0.38 nM for recombinant human AR . Ranirestat has the potential for

Ranirestat (AS-3201) potent and orally active aldose reductase (AR) inhibitor with IC 50 s of 11 nM and 15 nM for rat lens AR and recombinant human AR , respectively, and a K i of 0.38 nM for recombinant human AR . Ranirestat has the potential for

Ranirestat (AS-3201) potent and orally active aldose reductase (AR) inhibitor with IC 50 s of 11 nM and 15 nM for rat lens AR and recombinant human AR , respectively, and a K i of 0.38 nM for recombinant human AR . Ranirestat has the potential for

A gastroprotective histamine H2 receptor antagonist (pKi = 7.1) that decreases gastric acid secretion and inhibits intracellular cAMP production (IC₅₀ = 1 &microM).

A gastroprotective histamine H2 receptor antagonist (pKi = 7.1) that decreases gastric acid secretion and inhibits intracellular cAMP production (IC₅₀ = 1 &microM).

General description This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including MSDS and any product information leaflets have been developed and issued under the